People with atypical hemolytic uremic syndrome (aHUS) have an immune cell profile distinct from that of healthy people and unaffected family members, a recent study reported. Its scientists identified a range of immune cell types, genes, and signaling pathways that could ultimately serve as disease biomarkers — with the…
News
Short-term use of Soliris (eculizumab) successfully treated atypical hemolytic uremic syndrome (aHUS) that had no genetic link in two young adults, one with a rare infection and the other with a rare autoimmune condition, according to a case report. Both men lacked variants in complement genes that can…
People with atypical hemolytic uremic syndrome (aHUS) who start treatment with Soliris (eculizumab) or Ultomiris (ravulizumab) — both marketed by Alexion — generally use fewer healthcare resources, according to a new U.S. study. Indeed, rates of insurance claims for aHUS patients starting on either therapy dropped substantially…
Reduced capillary density and capillary abnormalities were identified in people with atypical hemolytic uremic syndrome (aHUS) using a nailfold dermoscopy, a study in Turkey reports. Nailfold dermoscopy is a noninvasive technique that lets doctors evaluate the small blood vessels (capillaries) in the nail fold. These observations suggest the technique…
Plasma exchange combined with rituximab, an immunosuppressant, might prevent atypical hemolytic uremic syndrome (aHUS) from coming back after a kidney transplant, according to a small study from India. The study, “Kidney Transplant Outcomes in Patients with Atypical Hemolytic Uremic Syndrome,” was published in Transplantation Proceedings. aHUS is…
Treatment with the drug Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) initially failed to ease the symptoms of a middle-age woman with AHUS and multiorgan involvement, a case study reported. Higher Soliris doses eventually eased disease symptoms in all organs except the kidneys, which had to be replaced…
A synthetic psychoactive drug was identified as the trigger that led to the onset of atypical hemolytic uremic syndrome (aHUS) in a 37-year-old man who was genetically prone to develop the condition, a case study in Croatia reported. “Our case is the first report of aHUS with proven ……
Pregnancy was identified as the trigger event for atypical hemolytic uremic syndrome (aHUS) that resulted in kidney damage for a genetically predisposed woman in her mid-20s, a U.S. case study reported. The patient had a clinical history of poorly managed high blood pressure and often failed to comply with…
A 38-year-old man developed atypical hemolytic uremic syndrome (aHUS) and end-stage kidney disease (ESKD) after receiving his first dose of AstraZeneca’s COVID-19 vaccine, according to a case report. The patient was admitted to a hospital in Saudi Arabia one week after being vaccinated. Tests revealed changes in blood parameters…
For the first time in South Korea, a patient who developed atypical hemolytic uremic syndrome (aHUS) after undergoing a kidney transplant was successfully treated with Soliris (eculizumab). “We report the first successful case of aHUS treatment in a kidney transplant recipient with early use of [Soliris] in South…
Recent Posts
- Heart complications were a puzzling part of my aHUS journey
- Inflammation of the pancreas may trigger aHUS, boy’s case shows
- Patients need more help to pay for rare disease treatment
- Man’s psoriasis triggers kidney failure, aHUS in rare overlap
- How inflammation from multiple conditions led to an eye emergency
- Early treatment critical in aHUS to prevent lasting kidney damage
- I struggle daily with deconditioning from my multiple illnesses
- Complement inhibitors show edge over plasma at stopping aHUS relapses
- Boy’s kidney issues resolve after Soliris treatment: Case report
- I’m learning to say, ‘There’s always tomorrow’ when I’m feeling guilty